Canadian Institutes of Health Research Project Grant: Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial. 2017-2022. Role: Co-Principal Investigator. Co-Principal Investigator: Dr. Marc Rodger.

Patient-Centered Outcomes Research Institute (PCORI) Grant: Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurrent Venous Thromboembolism: A Randomized Comparative Effectiveness Trial 2017-2021.
Role: Co-Principal Investigator. Co-Principal Investigators: Dr. Tom Ortel and Dr. David Garcia.

Continuing Health Science Education Program (CHSE) Research and Innovation Fund: Social Media for Knowledge Translation and Education 2 (SoME-KTE2): Assessing the feasibility of a novel, online needs assessment project to determine curricular design in the age of social media: 2016. Role: Co-Investigator. Principal Investigator: Dr. Teresa Chan.

ICRH Community Development Grants – Sleep and Circadian Rhythms and Venous Thromboembolic Diseases Clinical Trials Grant: 2015-2020. Role: Co-Applicant. Principal Investigators: Dr. Susan Kahn and Dr. Marc Rodger.

Comparison of Bleeding Between Rivaroxaban and Apixaban (COBBRA): Pilot project funded by CanVECTOR network: 2016-2017. Role: Principal Investigator.

The Ottawa Hospital Department of Medicine – Developmental Research Grant: Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Acute Venous Thromboembolism. 2015-2016.
Role: Principal Investigator. Co-Investigators: Dr. Marc Rodger and Dr. Alan Karovitch.

The Ottawa Hospital Department of Medicine – Developmental Research Grant: Determining the Safety of Enoxaparin Prophylaxis in Critically Ill Adults with Severe Renal Insufficiency. 2013-2014.
Role: Co-Investigator. Principal Investigators: Dr. Marc Carrier and Dr. Rakesh Patel.

The Ottawa Hospital Department of Medicine – Patient Quality and Safety Grant: Improving the Care of Patients Who Require Temporary Interruption of Anticoagulation.
2012-2013. Role: Co-Investigator. Principal Investigator: Dr. Phil Wells.